Kinetics of IgG Antibodies in Previous Cases of Dengue Fever—A Longitudinal Serological Survey
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Area
2.2. Study Design and Subjects Enrollment
2.3. Laboratory Methods
2.4. Data Analysis
3. Results
3.1. Study Population
3.2. Serum IgG antibody at 2 Follow-Up Visits
3.3. Univariate Analysis
3.4. Multivariate Analysis
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Guzman, M.G.; Harris, E. Dengue. Lancet 2015, 385, 453–465. [Google Scholar] [CrossRef]
- Bhatt, S.; Gething, P.W.; Brady, O.J.; Messina, J.P.; Farlow, A.W.; Moyes, C.L.; Drake, J.M.; Brownstein, J.S.; Hoen, A.G.; Sankoh, O.; et al. The global distribution and burden of dengue. Nature 2013, 496, 504–507. [Google Scholar] [CrossRef] [PubMed]
- Gubler, D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 1998, 11, 480–496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, B.; Liu, Q. Dengue fever in China. Lancet 2015, 385, 1621–1622. [Google Scholar] [CrossRef]
- Lai, S.J.; Huang, Z.J.; Zhou, H.; Anders, K.L.; Perkins, T.A.; Yin, W.E. The changing epidemiology of dengue in China, 1990–2014: A descriptive analysis of 25 years of nationwide surveillance data. BMC Med. 2015, 13, 100. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.J.; Yin, W.E.; Clements, A.; Williams, G.; Lai, S.J.; Zhou, H. Spatiotemporal analysis of indigenous and imported dengue fever cases in Guangdong province, China. BMC Infect. Dis. 2012, 12, 132. [Google Scholar] [CrossRef] [Green Version]
- Luo, L.; Liang, H.Y.; Hu, Y.S.; Zheng, X.L.; Liu, W.J.; Wang, Y.L.; Yang, Z.C. Epidemiological, virological, and entomological characteristics of dengue from 1978 to 2009 in Guangzhou, China. J. Vector Ecol. 2012, 37, 230–240. [Google Scholar] [CrossRef]
- Luo, L.; Jiang, L.Y.; Xiao, X.C.; Di, B.; Jing, Q.L.; Wang, S.Y.; Tang, J.L.; Wang, M.; Tang, X.P.; Yang, Z.C. The dengue preface to endemic in mainland China: The historical largest outbreak by Aedes albopictus in Guangzhou, 2014. Infect. Dis. Poverty 2017, 6, 148. [Google Scholar] [CrossRef]
- Bai, Z.; Liu, L.C.; Jiang, L. Evolutionary and phylodynamic analyses of Dengue virus serotype I in Guangdong Province, China, between 1985 and 2015. Virus Res. 2018, 256, 201–208. [Google Scholar] [CrossRef]
- Guy, B.; Barrere, B.; Malinowski, C.; Saville, M.; Teyssou, R.; Lang, J. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29, 7229–7241. [Google Scholar] [CrossRef]
- Sridhar, S.; Luedtke, A.; Langevin, E.; Zhu, M.; Bonaparte, M.; Machabert, T.; Savarino, S.; Zambrano, B.; Moureau, A.; Khromava, A.; et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 2018, 379, 327–340. [Google Scholar] [CrossRef] [PubMed]
- Nascimento, E.J.M.; Huleatt, J.W.; Cordeiro, M.T.; Castanha, P.M.S.; George, J.K.; Grebe, E.; Welte, A.; Brown, M.; Burke, D.S.; Marques, E.T.A. Development of antibody biomarkers of long term and recent dengue virus infections. J. Virol. Methods 2018, 257, 62–68. [Google Scholar] [CrossRef] [PubMed]
- Hu, D.M.; Di, B.; Ding, X.X.; Wang, Y.D.; Chen, Y.; Pan, Y.X.; Wen, K.; Wang, M.; Che, X.Y. Kinetics of non-structural protein 1, IgM and IgG antibodies in dengue type 1 primary infection. Virol. J. 2011, 8, 47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prince, H.E.; Matud, J.L. Estimation of dengue virus IgM persistence using regression analysis. Clin. Vaccine Immunol. 2011, 18, 2183–2185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kumar, A.; Nielsen, A.L. Trends in the patterns of IgM and IgG antibodies in febrile persons with suspected dengue in Barbados, an English-speaking Caribbean country, 2006–2013. J. Infect. Public Health 2015, 8, 583–592. [Google Scholar] [CrossRef] [PubMed]
- Cucunawangsih; Lugito, N.P.H.; Kurniawan, A. Immunoglobulin G (IgG) to IgM ratio in secondary adult dengue infection using samples from early days of symptoms onset. BMC Infect. Dis. 2015, 15, 276. [Google Scholar] [CrossRef] [Green Version]
- Hernández, D.L.C.; Isaac, S.; Hilario, F.A.; Silvia, G.M.; Irma, L.M.; Vianney, O.N.; Ludert, J.E.; Rosa, M.D.A. Viral load in patients infected with dengue is modulated by the presence of anti-dengue IgM antibodies. J. Clin. Virol. 2013, 58, 258–261. [Google Scholar] [CrossRef]
- Cuzzubbo, A.J.; Vaughn, D.W.; Nisalak, A.; Solomon, T.; Devine, P.L. Comparison of panbio dengue duo igm and igg capture elisa and venture technologies dengue igm and igg dot blot. J. Clin. Virol. 2000, 16, 135–144. [Google Scholar] [CrossRef]
- Luo, S.Y.; Cui, W.H.; Li, C.; Ling, F.; Fu, T.; Liu, Q.Y.; Ren, J.P.; Sun, J.M. Seroprevalence of dengue IgG antibodies in symptomatic and asymptomatic individuals three years after an outbreak in Zhejiang Province, China. BMC Infect. Dis. 2018, 1, 92. [Google Scholar] [CrossRef] [Green Version]
- Tun, M.M.N.; Muta, Y.; Inoue, S.; Morita, K. Persistence of neutralizing antibody against dengue virus 2 after 70 years from infection in Nagasaki. Biores. Open Access 2016, 5, 188–191. [Google Scholar] [CrossRef] [Green Version]
- Cropp, C.B.; Truong, T.T.; Imrie, A.; Effler, P.; Sukhbaatar, M.; Gurary, A.; Meeks, J. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol. 2007, 20, 672–675. [Google Scholar] [CrossRef] [Green Version]
- Katzelnick, L.C.; Montoya, M.; Gresh, L.; Balmaseda, A.; Harris, E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc. Natl. Acad. Sci. USA 2016, 113, 728–733. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, L.L.; Jing, Q.L.; Zeng, W.F.; Wang, M.; Cai, M.W.; Yang, C.H.; He, G.K.; Fan, J.W. The epidemic characteristics analysis of dengue fever in liwan district of guangzhou city in 2013. J. Trop. Med. 2014, 14, 1367–1369. (In Chinese) [Google Scholar]
- Yang, L.L.; Jing, Q.L.; Yang, C.H.; Cai, M.W.; Wang, M.; Zeng, W.F. The epidemiological characteristics of dengue fever in Liwan district of Guangzhou city in 2014. China Trop. Med. 2015, 15, 939–941. (In Chinese) [Google Scholar]
- Mengesha, T.M.; Beyene, B.; Ayele, W. Seroprevalence of yellow fever and related Flavi viruses in Ethiopia: A public health perspective. BMC Public Health 2018, 18, 1011. [Google Scholar] [CrossRef]
- Poland, J.D.; Calisher, C.H.; Monath, T.P.; Downs, W.G.; Murphy, K. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 1981, 59, 895–900. [Google Scholar] [CrossRef]
- Katzelnick, L.C.; Gresh, L.; Halloran, M.E.; Mercado, J.C.; Kuan, G.; Gordon, A.; Balmaseda, A.; Harris, E. Antibody-dependent enhancement of severe dengue disease in humans. Science 2017, 358, 929–932. [Google Scholar] [CrossRef] [Green Version]
- Guzman, M.G.; Alvarez, M.; Halstead, S.B. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: An historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 2013, 158, 1445–1459. [Google Scholar] [CrossRef]
- Dejnirattisai, W.; Jumnainsong, A.; Onsirisakul, N.; Fitton, P.; Vasanawathana, S.; Limpitikul, W.; Puttikhunt, C.; Edwards, C.; Duangchinda, T.; Supasa, S.; et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328, 745–748. [Google Scholar] [CrossRef] [Green Version]
- Vaughn, D.W.; Green, S.; Kalayanarooj, S.; Innis, B.L.; Nimmannitya, S.; Suntayakorn, S.; Endy, T.P.; Raengsakulrach, B.; Rothmanet, A.L.; Ennis, F.A.; et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181, 2–9. [Google Scholar] [CrossRef]
- Anderson, K.B.; Gibbons, R.V.; Cummings, D.A.T.; Nisalak, A.; Green, S.; Libraty, D.H.; Jarman, R.G.; Srikiatkhachorn, A.; Mammen, M.P.; Darunee, B.; et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J. Infect. Dis. 2014, 209, 360–368. [Google Scholar] [CrossRef] [PubMed]
- Reich, N.G.; Shrestha, S.; King, A.A.; Rohani, P.; Lessler, J.; Kalayanarooj, S.; Yoon, I.K.; Gibbons, R.V.; Burke, D.S.; Cummings, D.A.T. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J. R. Soc. Interface 2013, 10, 20130414. [Google Scholar] [CrossRef] [PubMed]
Factor | Number | Account (%) | |
---|---|---|---|
Gender | Male | 29 | 41.43 |
Female | 41 | 58.57 | |
Age in years | <60 years | 58 | 82.86 |
≥60 years | 12 | 17.14 | |
Education | Junior high school and below | 24 | 34.29 |
High school/technical secondary school | 23 | 32.86 | |
College and above | 23 | 32.86 | |
Occupation | Worker | 11 | 15.71 |
Professional technology/cadre/clerk | 13 | 18.57 | |
Business/Service staff | 15 | 21.43 | |
Other | 31 | 44.29 | |
Annual household income | Less than 30,000 | 14 | 20.00 |
30,000–60,000 | 20 | 28.57 | |
60,000–100,000 | 26 | 37.14 | |
More than 100,000 | 10 | 14.29 |
Variables | Total Number | First Follow-Up | χ2 | p | Second Follow-Up | χ2 | p | ||
---|---|---|---|---|---|---|---|---|---|
Positive Number | Positive Rate (%) | Positive Number | Positive Rate (%) | ||||||
Age in years | NA | NA | 0.578 | 0.447 | |||||
<60 | 58 | 58 | 100.00 | 56 | 96.55 | ||||
≥60 | 12 | 12 | 100.00 | 11 | 91.67 | ||||
Gender | NA | NA | 4.431 | 0.035 * | |||||
Male | 29 | 29 | 100.00 | 26 | 89.66 | ||||
Female | 41 | 41 | 100.00 | 41 | 100.00 |
Variables | First Follow-Up | t | p | Second Follow-Up | t | p | ||
---|---|---|---|---|---|---|---|---|
Average Value | Standard Deviation | Average Value | Standard Deviation | |||||
Age in years | 2.824 | 0.097 | 2.800 | 0.099 | ||||
<60 | 161.23 | 31.69 | 118.62 | 44.64 | ||||
≥60 | 182.52 | 25.20 | 126.48 | 61.58 | ||||
Gender | 0.373 | 0.543 | 11.603 | 0.001 * | ||||
Male | 162.39 | 33.84 | 114.15 | 61.09 | ||||
Female | 166.65 | 30.15 | 124.08 | 35.37 |
Follow-Up | Total IgG Antibody Positive Rate (%) | χ2 | p | Total IgG Antibody Concentration (Mean ± Standard Deviation) | Z | p |
---|---|---|---|---|---|---|
First | 100.00 | 3.066 | 0.080 | 164.89 ± 31.56 | 7.154 | <0.001 * |
Second | 95.71 | 119.97 ± 47.54 |
Factor | β | SE | χ2 | p | OR (95%CI) |
---|---|---|---|---|---|
Age in years | |||||
<60 | 1.0 | ||||
≥60 | −0.114 | 0.110 | 1.077 | 0.299 | 0.892 (0.719, 1.107) |
Gender | |||||
Male | 1.0 | ||||
Female | 0.032 | 0.083 | 0.147 | 0.702 | 1.032 (0.877, 1.215) |
Basic medical history | |||||
No | 1.0 | ||||
Yes | 0.218 | 0.076 | 8.126 | 0.004 * | 1.243 (1.070, 1.444) |
Vaccination | |||||
No | 1.0 | ||||
Yes | 0.146 | 0.127 | 1.321 | 0.250 | 1.158 (0.902, 1.485) |
First follow-up antibody concentration | 0.007 | 0.001 | 48.100 | <0.001 * | 1.008 (1.005, 1.010) |
Factor | β | SE | χ2 | p | OR (95%CI) |
---|---|---|---|---|---|
Basic medical history | |||||
No | 1.0 | ||||
Yes | 0.107 | 0.065 | 2.715 | 0.099 | 1.113 (0.980, 1.265) |
First follow-up antibody concentration | 0.007 | 0.001 | 40.089 | <0.001 * | 1.007 (1.005, 1.009) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wu, Q.; Jing, Q.; Wang, X.; Yang, L.; Li, Y.; Chen, Z.; Ma, M.; Yang, Z. Kinetics of IgG Antibodies in Previous Cases of Dengue Fever—A Longitudinal Serological Survey. Int. J. Environ. Res. Public Health 2020, 17, 6580. https://doi.org/10.3390/ijerph17186580
Wu Q, Jing Q, Wang X, Yang L, Li Y, Chen Z, Ma M, Yang Z. Kinetics of IgG Antibodies in Previous Cases of Dengue Fever—A Longitudinal Serological Survey. International Journal of Environmental Research and Public Health. 2020; 17(18):6580. https://doi.org/10.3390/ijerph17186580
Chicago/Turabian StyleWu, Qilin, Qinlong Jing, Xiujuan Wang, Lili Yang, Yilan Li, Zongqiu Chen, Mengmeng Ma, and Zhicong Yang. 2020. "Kinetics of IgG Antibodies in Previous Cases of Dengue Fever—A Longitudinal Serological Survey" International Journal of Environmental Research and Public Health 17, no. 18: 6580. https://doi.org/10.3390/ijerph17186580